Nanobiotix Announces the Presentation of the Final Efficacy

Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society...

Related Keywords

France , China , Massachusetts , United States , Cambridge , Cambridgeshire , United Kingdom , New York , Texas , Paris , France General , American , Victor Moreno , Omari Vivar , Anais Debard , Valentin Calugaru , Brandon Owens , Bernard Doger , Nathalie Badois , Anne Chilles , Emiliano Calvo , Louis Kayitalire , Xavier Liem , Christophe Le Tourneau , Nicolas Fakhry , Maria Lesnik , Leonarda Farber , Antoine Dubray Vautrin , Pierre Louis Germain , Wong Hee Kam , Ligia Vela Reid , Institut Curie , Linkedin , Drug Administration , French Financial Markets Authority Autorit , Euronext , Communications Department , University Of Texas Md Anderson Cancer Center , Investor Relations Department , Nasdaq , Twitter , Exchange Commission , Given The Company , Professor Christophe Le Tourneau , Annual Meeting , American Society , Progression Free , Overall Survival , Radiation Oncology , Laurent Levy , Novel Radioenhancer , Cisplatin Ineligible Locally Advanced , Final Results , Laetitia Finzi , Xavier Mirabel , Laetitia Houdas , Charlson Comorbidity Index , Progression Free Survival , Nanobiotix Head , United States Food , Fast Track , Cancer Center , Greater China , Asian Markets , Janssen Pharmaceutica , Euronext Paris , Nasdaq Global Select Market , New York City , Private Securities Litigation Reform Act , Annual Report , French Financial Markets Authority , Des March , Efficacy Readout , Primary Endpoints , Markets ,